Femasys Inc. - Common Stock (FEMY)
0.8000
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 9th, 8:54 PM EDT
Via Benzinga · June 6, 2025

Via Benzinga · June 4, 2025

The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Via Stocktwits · May 30, 2025

Via Benzinga · May 29, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · May 29, 2025

Via Benzinga · September 12, 2024
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.
Via Stocktwits · March 27, 2025

Via Benzinga · September 9, 2024

FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Via Benzinga · June 20, 2024

Via Benzinga · June 20, 2024

Via Benzinga · June 20, 2024

Via Benzinga · June 20, 2024

Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
Via Benzinga · June 17, 2024

FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 28, 2024

Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions.
Via Benzinga · February 21, 2024

Via Benzinga · February 19, 2024

Via Benzinga · February 8, 2024

Via Benzinga · February 7, 2024

Via Benzinga · December 14, 2023